A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma

BACKGROUND: IGV-001 is a personalized, autologous cancer cell-based immunotherapy conceived to deliver a tumor-derived antigenic payload in the context of immunostimulatory signals to patients with glioblastoma (GBM). IGV-001 consists of patient-derived GBM cells treated with an antisense oligodeoxy...

Descripción completa

Detalles Bibliográficos
Autores principales: Cultrara, Christopher, Uhl, Christopher, Kirby, Kenneth, Abed Elrazaq, Essam, Zellander, Amelia, Andrews, David W, Scott, Charles B, Galluzzi, Lorenzo, Exley, Mark A, Zilberberg, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407365/
https://www.ncbi.nlm.nih.gov/pubmed/37550054
http://dx.doi.org/10.1136/jitc-2023-006880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407365/
https://www.ncbi.nlm.nih.gov/pubmed/37550054
http://dx.doi.org/10.1136/jitc-2023-006880

Ejemplares similares